Evidence map›Paper›PMID 39610930›Full record

ArticleFrontiers in oncology2024

Development and validation of a MRI-radiomics-based machine learning approach in High Grade Glioma to detect early recurrence.

Fabrizio Pignotti, Tamara Ius, Rosellina Russo, Daniele Bagatto, Francesco Beghella Bartoli, Edda Boccia, Luca Boldrini, Silvia Chiesa, Chiara Ciardi, Davide Cusumano and 10 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Fabrizio Pignotti *Department of Neurosurgery, Mater Olbia Hospital, Olbia, Italy.
Tamara Ius *Neurosurgery Unit, Head-Neck and NeuroScience Department, University Hospital of Udine, Udine, Italy.
Rosellina RussoAdvanced Radiodiagnostics Centre, Unità Operativa Semplice Dipartimentale (UOSD) Neuroradiology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
Daniele BagattoDepartment of Neuroradiology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) "Santa Maria Della Misericordia", Udine, Italy.
Francesco Beghella BartoliDepartment of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
Edda BocciaDepartment of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
Luca BoldriniDepartment of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
Silvia ChiesaDepartment of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
Chiara CiardiDepartment of Neuroradiology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) "Santa Maria Della Misericordia", Udine, Italy.
Davide CusumanoMedical Physics Unit, Mater Olbia Hospital, Olbia, Italy.
Carolina GiordanoAdvanced Radiodiagnostics Centre, Unità Operativa Semplice Dipartimentale (UOSD) Neuroradiology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
Giuseppe La RoccaInstitute of Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
Ciro MazzarellaDepartment of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
Edoardo MazzucchiDepartment of Neurosurgery, Mater Olbia Hospital, Olbia, Italy.
Alessandro OliviInstitute of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome, Italy.
Miran SkrapNeurosurgery Unit, Head-Neck and NeuroScience Department, University Hospital of Udine, Udine, Italy.
Houng Elena TranDepartment of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
Giuseppe VarcasiaAdvanced Radiodiagnostics Centre, Unità Operativa Semplice Dipartimentale (UOSD) Neuroradiology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
Simona GaudinoInstitute of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University, Rome, Italy.
Giovanni SabatinoDepartment of Neurosurgery, Mater Olbia Hospital, Olbia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Patients diagnosed with High Grade Gliomas (HGG) generally tend to have a relatively negative prognosis with a high risk of early tumor recurrence (TR) after post-operative radio-chemotherapy. The assessment of the pre-operative risk of early versus delayed TR can be crucial to develop a personalized surgical approach. The purpose of this article is to predict TR using MRI radiomic analysis. Methods: Data were retrospectively collected from a database. A total of 248 patients were included based on the availability of 6-month TR results: 188 were used to train the model, the others to externally validate it. After manual segmentation of the tumor, Radiomic features were extracted and different machine learning models were implemented considering a combination of T1 and T2 weighted MR sequences. Receiver Operating Characteristic (ROC) curve was calculated with relative model performance metrics (accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV)) at the best threshold based on the Youden Index. Results: Models performance were evaluated based on test set results. The best model resulted to be the XGBoost, with an area under ROC curve of 0.72 (95% CI: 0.56 - 0.87). At the best threshold, the model exhibits 0.75 (95% CI: 0.63 - 0.75) as accuracy, 0.62 (95% CI: 0.38 - 0.83) as sensitivity 0.80 (95% CI: 0.66 - 0.89 as specificity, 0.53 (95% CI: 0.31 - 0.73) as PPV, 0.88 (95% CI: 0.72 - 0.94) as NPV. Conclusion: MRI radiomic analysis represents a powerful tool to predict late HGG recurrence, which can be useful to plan personalized surgical treatments and to offer pertinent patient pre-operative counseling.

Indexed as

high grade gliomamachine learningprognosisradiomicsrecurrence

Identifiers

PMID39610930
PMCPMC11602423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.